Indolent Non Follicular Lymphomas Prognostic Project

Prospective collection of data of possible prognostic relevance in patients with indolent non - follicular B-CELL Lymphomas.

Lead sponsor: Fondazione Italiana Linfomi - ETS•46 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

UNKNOWNPhase 3

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

NCT02991638 · Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 8, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment370

Start dateSep 2011

Last updatedAug 8, 2025

Condition

Indolent B-Cell Lymphomas

Locations shown

Vienna Univ Med Int I

Vienna

Center of Hematology and Hemotherapy, UNICAMP, University of Campinas

Campinas

Universidade Federal Do Rio de Janeiro

Rio de Janeiro

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions